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Background
Sulfamethoxazole hypersensitivity has been used as a
paradigm to study the role of drug metabolism in the
activation of T-cells. CD4+ T-cells isolated from blood/
skin of 100% of hypersensitive patients are activated with
the protein-reactive metabolite nitroso sulfamethoxazole
(SMX.NO). Since SMX.NO binds to multiple cellular
proteins it is assumed that peptides derived from the
modified protein interact with a number of diverse HLA
molecules to activate T-cells; however, the HLA mole-
cules that interact with SMX-NO modified peptides has
not been studied.
Method
The aims of this study were to examine the HLA mole-
cules that present SMX.NO (derived peptides) to T-cells
and determine the extent of alloreactivity. T-cell clones
were generated from 4 hypersensitive patients with cys-
tic fibrosis. Drug-specific proliferative responses and
cytokine secretion were measured using [3H]-thymidine
incorporation and ELISpot, respectively. Anti-human
class I and class II (DR, DP, and DQ) antibodies were
used to determine HLA restriction. Antigen presenting
cells expressing different HLAs were used to define the
alleles involved in the presentation of SMX.NO-derived
antigens to T-cells.
Results
A total of 976 clones were tested for SMX.NO reactivity.
Forty nine CD4+ clones were activated to proliferate and
secrete IFN-, IL-5, IL-13 and granzyme-B with SMX.NO.
No cross reactivity with SMX was observed. The
SMX.NO-specific response of clones was blocked with
antibodies against MHC class II and HLA-DQ. Clones
from 2 patients (Patient 1: HLA-DQB1*05:01:01G/
DQB1*06:03:01G; Patient 2: HLA-DQB1*02:01:01G/
DQB1*02:01:01G) were used to define the DQ alleles
involved in the presentation of SMX.NO derived antigens.
SMX.NO-specific responses were detected with antigen
presenting cells expressing HLA-DQB1*05 (patient 1) and
HLA-DQB1*02 (patient 2), but not other HLA-DQB1
alleles.
Conclusion
In conclusion, this study shows that HLA-DQ plays an
important role in the activation of SMX.NO-specific
T-cells from hypersensitive patients. T-cells from different
patients recognized the drug antigen associated with
different DQ alleles. However, clones from individual
patients were highly DQ allele restricted.
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